| Elliot Moore Tucker, MD | |
|
601 Childrens Ln, Norfolk, VA 23507-1910 | |
| (757) 668-7213 | |
| Not Available |
| Full Name | Elliot Moore Tucker |
|---|---|
| Gender | Male |
| Speciality | Pediatrics - Pediatric Cardiology |
| Location | 601 Childrens Ln, Norfolk, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265639306 | NPI | - | NPPES |
| 02032548 | Medicaid | MS | |
| 1265639306 | Medicaid | VA | |
| 1193186 | Medicaid | LA | |
| 89066JW | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080P0202X | Pediatrics - Pediatric Cardiology | 0101234827 (Virginia) | Primary |
| Entity Name | University Of Virginia Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033138250 PECOS PAC ID: 4880590728 Enrollment ID: O20040102000780 |
News Archive
Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.
With new funding from The Mayday Fund, a Saint Louis University researcher will leverage her discovery of a pain pathway to determine if either of two key molecules can be used as biomarkers for pain associated with four debilitating health conditions: chemotherapy-induced peripheral neuropathy, endometriosis, interstitial cystitis and vulvodynia.
Teenagers who share their parent's understanding of parent-decreed driving rules are less likely to take risks behind the wheel, according to a new study from researchers at the University of Maryland.
Osteologix Inc. announced today that the company anticipates that it will be prepared to file a marketing application in 2011 in the European Union for its proprietary second-generation strontium therapy, NB S101 (strontium malonate). If successful, this will be Osteologix' first marketing approval of NB S101 for the treatment of postmenopausal osteoporosis.
Early physical therapy for recent-onset low back pain resulted in statistically significant improvement in disability compared to usual care, but the improvement was modest and did not achieve a difference considered clinically important at the individual patient level, according to a study in the October 13 issue of JAMA.
› Verified 8 days ago
| Entity Name | Childrens Specialty Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255354130 PECOS PAC ID: 5890788764 Enrollment ID: O20040406001195 |
News Archive
Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.
With new funding from The Mayday Fund, a Saint Louis University researcher will leverage her discovery of a pain pathway to determine if either of two key molecules can be used as biomarkers for pain associated with four debilitating health conditions: chemotherapy-induced peripheral neuropathy, endometriosis, interstitial cystitis and vulvodynia.
Teenagers who share their parent's understanding of parent-decreed driving rules are less likely to take risks behind the wheel, according to a new study from researchers at the University of Maryland.
Osteologix Inc. announced today that the company anticipates that it will be prepared to file a marketing application in 2011 in the European Union for its proprietary second-generation strontium therapy, NB S101 (strontium malonate). If successful, this will be Osteologix' first marketing approval of NB S101 for the treatment of postmenopausal osteoporosis.
Early physical therapy for recent-onset low back pain resulted in statistically significant improvement in disability compared to usual care, but the improvement was modest and did not achieve a difference considered clinically important at the individual patient level, according to a study in the October 13 issue of JAMA.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elliot Moore Tucker, MD 601 Childrens Ln, Norfolk, VA 23507-1910 Ph: (757) 668-7213 | Elliot Moore Tucker, MD 601 Childrens Ln, Norfolk, VA 23507-1910 Ph: (757) 668-7213 |
News Archive
Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.
With new funding from The Mayday Fund, a Saint Louis University researcher will leverage her discovery of a pain pathway to determine if either of two key molecules can be used as biomarkers for pain associated with four debilitating health conditions: chemotherapy-induced peripheral neuropathy, endometriosis, interstitial cystitis and vulvodynia.
Teenagers who share their parent's understanding of parent-decreed driving rules are less likely to take risks behind the wheel, according to a new study from researchers at the University of Maryland.
Osteologix Inc. announced today that the company anticipates that it will be prepared to file a marketing application in 2011 in the European Union for its proprietary second-generation strontium therapy, NB S101 (strontium malonate). If successful, this will be Osteologix' first marketing approval of NB S101 for the treatment of postmenopausal osteoporosis.
Early physical therapy for recent-onset low back pain resulted in statistically significant improvement in disability compared to usual care, but the improvement was modest and did not achieve a difference considered clinically important at the individual patient level, according to a study in the October 13 issue of JAMA.
› Verified 8 days ago
Joshua Wayne Gollub, Pediatrics Medicare: Medicare Enrolled Practice Location: 601 Childrens Ln, Norfolk, VA 23507 Phone: 757-668-7000 | |
Stephen C. Restaino, DO Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 601 Childrens Ln, Norfolk, VA 23507 Phone: 757-668-7179 Fax: 757-668-9810 | |
Michael Lee Smith, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 601 Childrens Ln, Norfolk, VA 23507 Phone: 757-668-7456 Fax: 757-668-9255 | |
Phyllis R. Hope, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 601 Childrens Ln, Norfolk, VA 23507 Phone: 757-668-7456 Fax: 757-668-9255 | |
Linda D Pegram, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 601 Childrens Ln, Norfolk, VA 23507 Phone: 757-668-7007 Fax: 757-668-8658 | |
Ernette Yvonne Benson-foulk, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6345 Center Dr, Building 14, Norfolk, VA 23502 Phone: 757-461-4027 Fax: 757-461-8821 | |
Monica G Baker, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 601 Childrens Ln, Norfolk, VA 23507 Phone: 757-668-7456 Fax: 757-668-9255 |